Drug Profile
Exenatide/insulin long acting - Hanmi Pharmaceutical
Alternative Names: LAPSInsulin Combo; LAPSInsulin115/LAPSCA-Exendine4; HM-14220; Insulin/exenatide long-acting - Hanmi Pharmaceutical; Long-acting insulin 115/exendin-4 combination - Hanmi PharmaceuticalLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (Parenteral)
- 24 Mar 2021 Preclinical development in Type 2 diabetes mellitus is still ongoing in South Korea (Parenteral) (Hanmi Pharmaceutical's pipeline, March 2021)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (Parenteral)